Гормональна терапія первинної оваріальної недостатності Погляд комітету експертів Американського коледжу акушерів і гінекологів
Бічна панель сторінки статті
Основний зміст сторінки статті
Анотація
Даний документ розроблено Комітетом Американського коледжу акушерів і гінекологів та комітетом з гінекологічної практики у співпраці з членом комітету Samantha F. Butts, MD, MSCE. Він відображає нові клінічні та наукові досягнення станом на дату випуску та може бути змінений. Інформація, яка наведена в ньому, не повинна сприйматись як така, що є винятковою для обов’язкового дотримання принципів лікування або тактики ведення.
Блок інформації про статтю
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Автори зберігають авторське право, а також надають журналу право першого опублікування оригінальних наукових статей на умовах ліцензії Creative Commons Attribution 4.0 International License, що дозволяє іншим розповсюджувати роботу з визнанням авторства твору та першої публікації в цьому журналі.
Посилання
Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360:606-14.
Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68(4):499-509. doi: 10.1111/j.1365-2265.2007.03073.x.
Committee Opinion No. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193-7. doi: 10.1097/01.AOG.0000451757.51964.98.
Laml T, Preyer O, Umek W, Hengstschlager M, Hanzal H. Genetic disorders in premature ovarian failure. Hum Reprod Update. 2002;8(5):483-91. doi: 10.1093/humupd/8.5.483.
Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/ epicanthus inversus syndrome. Nat Genet. 2001;27(2):159-66. doi: 10.1038/84781.
Fraser IS, Shearman RP, Smith A, Russell P. An association among blepharophimosis, resistant ovary syndrome, and true premature menopause. Fertil Steril. 1988;50(5):747-51. doi: 10.1016/s0015-0282(16)60309-6.
Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97(3):189-94. doi: 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J.
Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab. 2004;89(9):4569-74. doi: 10.1210/jc.2004-0347.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376:911-21.
Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol. 2005;162(11):1089-97. doi: 10.1093/aje/kwi324.
Snowdon DA, Kane RL, Beeson WL, Burke GL, Sprafka JM, Potter J, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health. 1989;79(6):709-14. doi: 10.2105/ajph.79.6.709.
Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998;91(1):12-5. doi: 10.1016/s0029-7844(97)00583-8.
Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause. 2007;14(3 Pt 2):567-71. doi: 10.1097/gme.0b013e31804c793d.
Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009;94(7):2277-83. doi: 10.1210/jc.2008-1878.
Vega EM, Egea MA, Mautalen CA. Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas. 1994;19(2):117-24. doi: 10.1016/0378-5122(94)90061-2.
Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int. 1991;49(2):90-4. doi: 10.1007/BF02565127.
Tuppurainen M, Kroger H, Honkanen R, Puntila E, Huopio J, Saarikoski S, et al. Risks of perimenopausal fractures – a prospective population-based study. Acta Obstet Gynecol Scand. 1995;74(8):624-8. doi: 10.3109/00016349509013475.
Van der Klift M, de Laet CE, McCloskey EV, Johnell O, Kanis JA, Hofman A, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2004;19(7):1172-80. doi: 10.1359/JBMR.040215.
Leite-Silva P, Bedone A, Pinto-Neto AM, Costa JV, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet. 2009;280(2):177-81. doi: 10.1007/s00404-008-0881-3.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45. doi: 10.4065/83.9.1032.
Atsma F, Bartelink ML, Grobbee DE, Van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13(2):265-79. doi: 10.1097/01.gme.0000218683.97338.ea.
Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89(2):157-61. doi: 10.7326/0003-4819-89-2-157.
Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67(1):30-5. doi: 10.1210/ jcem-67-1-30.
Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 1990;12(4):321-31. doi: 10.1016/0378-5122(90)90012-u.
Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999;52(4):303-7. doi: 10.1016/s0895-4356(98)00170-x.
De Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, Van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol. 2002;155(4):339-45. doi: 10.1093/aje/155.4.339.
Van der Schouw YT, Van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347(9003):714-8. doi: 10.1016/s0140-6736(96)90075-6.
Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004;89(8):3907-13. doi: 10.1210/jc.2004-0015.
Ostberg JE, Storry C, Donald AE, Attar MJ, Halcox JP, Conway GS. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf). 2007;66(4):557-64. doi: 10.1111/j.1365-2265.2007.02772.x.
Langrish JP, Mills NL, Bath LE, Warner P, Webb DJ, Kelnar CJ, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53(5):805-11. doi: 10.1161/hypertensionaha.108.126516.
Butts S, Riethman H, Ratcliffe S, Shaunik A, Coutifaris C, Barnhart K. Correlation of telomere length and telomerase activity with occult ovarian insufficiency. J Clin Endocrinol Metab. 2009;94(12):4835-43. doi: 10.1210/jc.2008-2269.
Rebar RW. Premature ovarian failure. Obstet Gynecol. 2009;113:1355-63.
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, De Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurol. 2007;69(11):1074-83. doi: 10.1212/01.wnl.0000276984.19542.e6.
Ross JL, Stefanatos GA, Kushner H, Bondy C, Nelson L, Zinn A, et al. The effect of genetic differences and ovarian failure: intact cognitive function in adult women with premature ovarian failure versus turner syndrome. J Clin Endocrinol Metab 2004;89(4):1817-22. doi: 10.1210/jc.2003-031463.
Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric. 2011;14(4):428-37. doi: 10.3109/13697137.2011.571320.
Benetti-Pinto CL, de Almeida DM, Makuch MY. Quality of life in women with premature ovarian failure. Gynecol Endocrinol. 2011;27(9):645-9. doi: 10.3109/09513590.2010.520374.
Orshan SA, Ventura JL, Covington SN, Vanderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. Fertil Steril. 2009;92(2):688-93. doi: 10.1016/j.fertnstert.2008.07.1718.
Groff AA, Covington SN, Halverson LR, Fitzgerald OR, Vanderhoof V, Calis K, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril. 2005;83(6):1734-41. doi: 10.1016/j.fertnstert.2004.11.067.
Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, social anxiety, and impaired selfesteem in Turner syndrome and premature ovarian failure. JAMA. 2006;295(12):1374-6. doi: 10.1001/jama.295.12.1374.
Mann E, Singer D, Pitkin J, Panay N, Hunter MS. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 2012;15(5):481-9. doi: 10.3109/13697137.2011.647841.
No authors listed. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208.
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Million Women Study. Lancet. 2003;362(9382):419-27. doi: 10.1016/s0140-6736(03)14065-2.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804-10. doi: 10.1200/JCO.2004.00.8151.
Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev. 1993;15:80-97.
Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer. Review and meta-analysis. Cancer. 1990;66(11):2253-63. doi: 10.1002/1097-0142(19901201)66:11<2253::aid-cncr2820661102>3.0.co;2-g.
Thomas DB. Oral contraceptives and breast cancer: review of the epidemiologic literature. Contraception. 1991;43: 597-642.
Rosenberg L, Miller DR, Kaufman DW, Helmrich SP, Stolley PD, Schottenfeld D, et al. Breast cancer and oral contraceptive use. Am J Epidemiol. 1984;119:167-76.
Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, et al. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst 1989;8(1):1313-21. doi: 10.1093/jnci/81.17.1313.
Paul C, Skegg DC, Spears GF. Oral contraceptives and risk of breast cancer. Int J Cancer. 1990;46:366-73.
No authors listed. Oral contraceptive use and breast cancer risk in young women. UK National Case-Control Study Group. Lancet. 1989;1(8645):973-82.
Shelton JD. Breast cancer and combined oral contraceptives. Br J Cancer. 1990;62:468-70.
Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989;59(4):613-7. doi: 10.1038/bjc.1989.124.
McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987;56(5):653-60. doi: 10.1038/bjc.1987.261.
Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer. 1989;59:618-21.
Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol. 1986;68(6):863-8.
Meirik O, Lund E, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet. 1986;2(8508):650-4. doi: 10.1016/s0140-6736(86)90166-2.
Paffenbarger RS Jr, Kampert JB, Chang HG. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol. 1980;112(2):258-68. doi: 10.1093/oxfordjournals.aje.a112992.
Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol. 1994;170(5 Pt 1):1213-23. doi: 10.1016/s0002-9378(94)70129-6.
Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril. 1982;37(1):79-82. doi: 10.1016/s0015-0282(16)45981-9.
Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989;161(6 Pt2):1859-64. doi: 10.1016/s0002-9378(89)80007-9.
Beral V, Bull D, Reeves G. Endometrial cancer and hormonereplacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet. 2005;365(9470):1543-51. doi: 10.1016/S0140-6736(05)66455-0.
Endometrial cancer. Practice Bulletin No. 149. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2015;125:1006-26.
Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338(8762):274-7. doi: 10.1016/0140-6736(91)90417-n.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Writing Group for the Women’s Health Initiative Investigators. JAMA 2002;288(3):321-33. doi: 10.1001/jama.288.3.321.
Fritz MA, Speroff L. Clinical and gynecologic endocrinology and infertility. 8th ed. Philadelphia (PA): Wolters Kluwer/Lippincott Williams & Wilkins; 2011.
Management of menopausal symptoms. Practice Bulletin No. 141. Obstet Gynecol. 2014;123(1):202-16. doi: 10.1097/01.AOG.0000441353.20693.78.
Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, et al. Biologic effects of transdermal estradiol. N Engl J Med. 1986;314(25):1615-20. doi: 10.1056/NEJM198606193142505.
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Circulation. 2007;115(7):840-5. doi: 10.1161/CIRCULATIONAHA.106.642280.
No authors listed. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Committee Opinion No. 556. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2013;121(4):887-90. doi: 10.1097/01.AOG.0000428645.90795.d9.
Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011;128(7):1644-51. doi: 10.1002/ijc.25762.